| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aljoša Bave. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life sciences. vol 99. issue 1-2. 2014-05-05. PMID:24412390. |
contrary, glp-1 mimetic therapy improves postprandial glycaemia without the hypoglycaemia and weight gain associated with aggressive insulin therapy. |
2014-05-05 |
2023-08-12 |
Not clear |
| Aljoša Bave. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life sciences. vol 99. issue 1-2. 2014-05-05. PMID:24412390. |
thus, a right combination of basal insulin which has lowering effect on fasting plasma glucose and glp-1 mimetic with its lowering effect on postprandial plasma glucose with minimal gastrointestinal adverse effects, seems the right therapy choice from a clinical point of view for some diabetic patients. |
2014-05-05 |
2023-08-12 |
Not clear |
| Aljoša Bave. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life sciences. vol 99. issue 1-2. 2014-05-05. PMID:24412390. |
in this article, we discuss the pros and cons of the use of insulin analogues and glp-1 mimetics that are associated with the treatment of type 2 diabetes. |
2014-05-05 |
2023-08-12 |
Not clear |
| Naim Shehadeh, Eena Daich, Nehama Zuckerman-Levi. Can GLP-1 preparations be used in children and adolescents with diabetes mellitus? Pediatric endocrinology reviews : PER. vol 11. issue 3. 2014-05-01. PMID:24716398. |
glucagon-like peptide-1 (glp-1) is secreted from the gut after meals and enhances glucose-induced insulin secretion, inhibits glucagon secretion, suppresses appetite, and delays the gastric-emptying rate. |
2014-05-01 |
2023-08-13 |
human |
| Yao Dai, Jawahar L Mehta, Mingwei Che. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovascular drugs and therapy. vol 27. issue 5. 2014-04-28. PMID:23657563. |
glucagon-like peptide-1 (glp-1) activation stimulates insulin secretion and may prevent atherosclerosis by increasing enos synthesis. |
2014-04-28 |
2023-08-12 |
Not clear |
| Serenella Salinari, Carel W le Roux, Alessandro Bertuzzi, Francesco Rubino, Geltrude Mingron. Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. Diabetes. vol 63. issue 3. 2014-04-24. PMID:24241532. |
baseline and poststimulation levels of glucose, insulin, glucagon-like peptide 1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) were measured. |
2014-04-24 |
2023-08-12 |
rat |
| Benedikt A Aulinger, Anne Bedorf, Gabriele Kutscherauer, Jocelyn de Heer, Jens J Holst, Burkhard Göke, Jörg Schirr. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes. vol 63. issue 3. 2014-04-24. PMID:24296715. |
thus, in this cohort of t2d patients with a substantial ie, glp-1 contributed ∼ 50% to the insulin excursion after an ogtt with and without dpp-4 inhibition. |
2014-04-24 |
2023-08-12 |
Not clear |
| A J Schee. [Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action]. Revue medicale de Liege. vol 69. issue 2. 2014-04-24. PMID:24683832. |
the latter interesting combination should tackle fasting glycaemia with basal insulin (after appropriate dose titration) and postprandial hyperglycaemia with the glp-1 receptor agonist in a complementary manner. |
2014-04-24 |
2023-08-12 |
Not clear |
| Chong Gao, Yueze Liu, Lin Li, Christian Hölsche. New animal models of Alzheimer's disease that display insulin desensitization in the brain. Reviews in the neurosciences. vol 24. issue 6. 2014-04-22. PMID:24259244. |
based on these findings, several ongoing clinical trials are testing long lasting insulin analogues or glp-1 mimetics in patients with ad. |
2014-04-22 |
2023-08-12 |
mouse |
| Shu Meguro, Toshihide Kawai, Tomohiro Matsuhashi, Motoaki Sano, Keiichi Fukuda, Hiroshi Itoh, Yoshihiko Suzuk. Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis. International journal of endocrinology. vol 2014. 2014-04-16. PMID:24738001. |
we investigated the efficacy of basal-supported oral therapy (bot) with insulin glargine and sitagliptin for counteracting glp-1 tachyphylaxis. |
2014-04-16 |
2023-08-13 |
human |
| Shu Meguro, Toshihide Kawai, Tomohiro Matsuhashi, Motoaki Sano, Keiichi Fukuda, Hiroshi Itoh, Yoshihiko Suzuk. Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis. International journal of endocrinology. vol 2014. 2014-04-16. PMID:24738001. |
their glp-1 analog-based therapy was switched to bot with insulin glargine plus sitagliptin and other medications. |
2014-04-16 |
2023-08-13 |
human |
| Sachin L Badole, Swapnil M Chaudhari, Pranita P Bagul, Sagar P Mahamuni, Rekha D Khose, Anuja C Joshi, Chandrashekhar G Raut, Anand A Zanwa. Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats. PloS one. vol 8. issue 8. 2014-04-15. PMID:24023648. |
glycosylated haemoglobin, lipid profile, plasma and colonic active (glp-1) (7-36) amide, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress were measured after 8(th) week treatment. |
2014-04-15 |
2023-08-12 |
rat |
| Sachin L Badole, Swapnil M Chaudhari, Pranita P Bagul, Sagar P Mahamuni, Rekha D Khose, Anuja C Joshi, Chandrashekhar G Raut, Anand A Zanwa. Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats. PloS one. vol 8. issue 8. 2014-04-15. PMID:24023648. |
both concomitant treatment increased plasma and pancreatic insulin as well as plasma and colonic active (glp-1) (7-36) amide secretion. |
2014-04-15 |
2023-08-12 |
rat |
| D Rondas, W D'Hertog, L Overbergh, C Mathie. Glucagon-like peptide-1: modulator of β-cell dysfunction and death. Diabetes, obesity & metabolism. vol 15 Suppl 3. 2014-04-14. PMID:24003936. |
glucagon-like peptide-1 (glp-1) is one of the hormones responsible for the incretin effect, a term that refers to the observation that orally administered glucose results in a larger increase in plasma insulin levels and insulin-dependent decrease in blood glucose concentration when compared to the same amount of glucose given intravenously. |
2014-04-14 |
2023-08-12 |
Not clear |
| D Rondas, W D'Hertog, L Overbergh, C Mathie. Glucagon-like peptide-1: modulator of β-cell dysfunction and death. Diabetes, obesity & metabolism. vol 15 Suppl 3. 2014-04-14. PMID:24003936. |
upon secretion, glp-1 targets different cell types and exerts a wide variety of actions such as potentiation of glucose-stimulated insulin secretion, reduction of appetite, delay of gastric emptying and increase in β-cell mass. |
2014-04-14 |
2023-08-12 |
Not clear |
| Sara Chowdhury, Dominic N Reeds, Dan L Crimmins, Bruce W Patterson, Erin Laciny, Songyan Wang, Hung D Tran, Terry A Griest, David A Rometo, Judit Dunai, Michael J Wallendorf, Jack H Ladenson, Kenneth S Polonsky, Burton M Wic. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. American journal of physiology. Gastrointestinal and liver physiology. vol 306. issue 4. 2014-04-10. PMID:24356886. |
plasma acm, glucose, insulin, c-peptide, glucagon, xen, gip, and glucagon-like peptide-1 (glp-1) levels were measured and isrs calculated. |
2014-04-10 |
2023-08-12 |
human |
| Sara Chowdhury, Dominic N Reeds, Dan L Crimmins, Bruce W Patterson, Erin Laciny, Songyan Wang, Hung D Tran, Terry A Griest, David A Rometo, Judit Dunai, Michael J Wallendorf, Jack H Ladenson, Kenneth S Polonsky, Burton M Wic. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. American journal of physiology. Gastrointestinal and liver physiology. vol 306. issue 4. 2014-04-10. PMID:24356886. |
hi-xen reduced plasma glp-1, but not gip, levels without altering the insulin secretory response to glucose. |
2014-04-10 |
2023-08-12 |
human |
| Sara Chowdhury, Dominic N Reeds, Dan L Crimmins, Bruce W Patterson, Erin Laciny, Songyan Wang, Hung D Tran, Terry A Griest, David A Rometo, Judit Dunai, Michael J Wallendorf, Jack H Ladenson, Kenneth S Polonsky, Burton M Wic. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. American journal of physiology. Gastrointestinal and liver physiology. vol 306. issue 4. 2014-04-10. PMID:24356886. |
moreover, endogenous glp-1 may not be a major enhancer of insulin secretion in healthy humans under physiological conditions. |
2014-04-10 |
2023-08-12 |
human |
| Dieter Rondas, Marco Bugliani, Wannes D'Hertog, Kasper Lage, Mathilde Masini, Etienne Waelkens, Piero Marchetti, Chantal Mathieu, Lut Overberg. Glucagon-like peptide-1 protects human islets against cytokine-mediated β-cell dysfunction and death: a proteomic study of the pathways involved. Journal of proteome research. vol 12. issue 9. 2014-04-08. PMID:23937086. |
co-incubation of cytokine-treated human islets with glp-1 resulted in a marked protection of β-cells against cytokine-induced apoptosis and significantly attenuated cytokine-mediated inhibition of glucose-stimulated insulin secretion. |
2014-04-08 |
2023-08-12 |
human |
| Adam P Chambers, Eric P Smith, Denovan P Begg, Bernadette E Grayson, Stephanie Sisley, Todd Greer, Joyce Sorrell, Lisa Lemmen, Kati LaSance, Stephen C Woods, Randy J Seeley, David A D'Alessio, Darleen A Sandova. Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy. American journal of physiology. Endocrinology and metabolism. vol 306. issue 4. 2014-04-08. PMID:24368666. |
rapid, early rises of circulating insulin and glucagon-like peptide-1 (glp-1) concentrations following food ingestion are characteristic of these procedures. |
2014-04-08 |
2023-08-12 |
rat |